Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.

NHC Communications, Inc. manufactures network switching and test equipment for local telecom service providers, corporations and multi-tenant buildings. It also offers the XPoint product line geared for smaller network applications. The company was founded in 1986 and is headquartered in Mount-Royal, Canada

EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one of the two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains.

METabolic EXplorer is a biochemistry company that develops industrial alternatives to petrochemical processes. It offers chemical manufacturers viable, long-term alternatives based on renewable resources. METabolic EXplorer considers the economic performance of each production process to be a fundamental factor of competitiveness in relation to petrochemical processes. It is continually working to improve the efficiency of microorganisms and to make its technologies more competitive, notably by diversifying the supply of renewable raw materials. The company aims to produce basic chemical compounds that already have a large number of industrial applications essential to everyday life.

Daiichi Pharmaceutical Co. Ltd. manufactured pharmaceutical products. It used to make prescription drugs, OTC treatments and animal health products. The firm's prescription drugs included treatments for allergies, hypertension and stroke; it also has drugs in clinical trials. It was founded in 1915 and was located in Tokyo, Japan.

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

Kingston General Hospital operates as a teaching hospital, which provides complex-acute and specialty care services, conducts research, and trains healthcare professionals. It offers cancer, cardiac, critical, diagnostic imaging, emergency, medicine, mental health, obstetrical, pediatric, pharmacy, and surgical care services, laboratory services, and other regional healthcare programs. The company was founded in 1831 and is headquartered in Ontario, Canada.

Delta Biotechnology Ltd., a subsidiary of Novozymes A/S, is a company headquartered in Windlesham, UK. The firm produces and markets a range of valuable proteins from yeast using low cost manufacturing technologies. It was acquired by Novozymes An on July 06, 2006.

Albumedix A/S is a private company headquartered in Copenhagen, Denmark, that operates as a biotechnology company.

Zhaoqing Dahuanong Biopharmaceutical Co., Ltd., established on 2002-07-22, The business scope includes the production of veterinary vaccines;sales of veterinary drugs;Technical Services;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).The branch produces inactivated embryotoxin vaccines;Sales of veterinary biological products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kikkoman Corp. is a holding company which engages in the food manufacturing business. It operates through the following segments: Domestic Foods-Manufacturing and Sales, Domestic Others, Overseas Foods-Manufacturing and Sales, and Overseas Foods-Wholesale. The Domestic Foods-Manufacturing and Sales segment manufactures and sells soy sauce, beverages, and alcoholic beverages. The Domestic Others segment involves in the production and sale of clinical diagnostic reagents, hygiene inspection agents, processing enzymes and chemical products such as hyaluronic acid. It also operates in real estate property leasing, logistics, and back-office support for Kikkoman Group, and other businesses. The Overseas Foods-Manufacturing and Sales segment sells soy sauce, Del Monte products, and overseas health foods. The Overseas Food-Wholesale segment purchases and sells oriental food products in Japan and overseas. The company was founded on December 7, 1917 and is headquartered in Noda, Japan.

Innovative Cellular Therapeutics Co., Ltd. is a Chinese company located in Shanghai that operates as a biotechnology company that develops cellular immunotherapies for the treatment of solid tumors. It was founded in 2009 by Lei Xiao and Zhao Wu. Lei Xiao has been the CEO since that date.\nThe company says this about itself: Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR® solid tumor CAR-T platform technology. ICT has already achieved promising responses with CoupledCAR® in third-line colorectal and third-line thyroid cancer patients in ongoing clinical proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through the Company’s Shanghai-based R&D center. ICT received its first U.S. Investigational New Drug (IND) application clearance for its ICTCAR014 program in late 2019. ICTCAR014 is based on ICT’s in-house developed proprietary ArmoredCAR® liquid tumor CAR-T platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells.

Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.

MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX.

Vysis develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The Company has assembled a management team experienced in developing,commercializing and marketing DNA based diagnostic products and associated genetic workstations. The Company was the first to obtain Food and Drug Administration ("FDA") clearance for a genomic product using fluorescence INSITU hybridization ("FISH"). Vysis currently markets four FDA cleared clinical products in addition to distributing over 240 research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 28 countries. It has an installed base of over 320 proprietary genetic workstations at 224 laboratories in 18 countries. The Company has a pipeline of nine clinical products under development and an expanding list of clinical product leads based upon its collaborations with leading medical research institutions, which include the University of California, San Francisco, the Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago and the Reproductive Genetics Institute.

Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. Its products include electronic films, repellent products, and agriculture products such as traditional synthetic nitrogen fertilizers and traditional chemical-based crop protection products. The company was founded by Zachariah Serber, Jed Dean and Joshua J. Hoffman in 2013 and is headquartered in Emeryville, CA.

OPX Biotechnologies, Inc. is a Colorado-based bioproducts company using proprietary bioengineering technology to convert renewable feedstocks into biofuels and green chemistry products. The OPX EDGE - Efficiency Directed Genome Engineering - technology platform rapid, rational, and robust optimization of microbes and bioprocesses to achieve equivalent product performance with improved sustainability at lower cost versus petroleum based alternatives.